Gene therapy for breast cancer

Shunji Takahashi, Kiyohiko Hatake, Yoshikazu Sugimoto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Breast cancer is sensitive to chemotherapy and endocrine therapy, but the prognosis of advanced or relapsed breast cancer is unsatisfactory. Gene therapy is promising as another useful therapeutic approach for advanced breast cancer. Strategies of gene therapy for breast cancer in ongoing clinical protocols can be divided into four: (1) suppression of oncogenes or transduction of tumor suppressors; (2) enhancement of immunological response to cancer cells; (3) transduction of suicide genes; and (4) protection of bone marrow using drug resistance genes. We have started a clinical study of gene therapy for breast cancer using multidrug resistance gene (MDR1), in which advanced or relapsed breast cancer patients received high dose chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT) with MDR1-transduced hemopoietic cells, and then were treated with docetaxel. Two patients have been treated so far, and in vivo enrichment of MDR1-transduced cells with docetaxel treatment after PBSCT was seen in both cases. Both patients are in complete remission and have no apparent adverse effect from MDR1 gene transduction.

Original languageEnglish
Pages (from-to)468-477
Number of pages10
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume30
Issue number4
Publication statusPublished - 2003 Apr
Externally publishedYes

Fingerprint

Genetic Therapy
docetaxel
Breast Neoplasms
Peripheral Blood Stem Cell Transplantation
Genes
MDR Genes
Drug Therapy
Clinical Protocols
Oncogenes
Drug Resistance
Suicide
Neoplasms
Therapeutics
Bone Marrow

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Gene therapy for breast cancer. / Takahashi, Shunji; Hatake, Kiyohiko; Sugimoto, Yoshikazu.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 30, No. 4, 04.2003, p. 468-477.

Research output: Contribution to journalArticle

Takahashi, S, Hatake, K & Sugimoto, Y 2003, 'Gene therapy for breast cancer', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 30, no. 4, pp. 468-477.
Takahashi, Shunji ; Hatake, Kiyohiko ; Sugimoto, Yoshikazu. / Gene therapy for breast cancer. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2003 ; Vol. 30, No. 4. pp. 468-477.
@article{dbe01632b6b9483f815572d87fbd31d4,
title = "Gene therapy for breast cancer",
abstract = "Breast cancer is sensitive to chemotherapy and endocrine therapy, but the prognosis of advanced or relapsed breast cancer is unsatisfactory. Gene therapy is promising as another useful therapeutic approach for advanced breast cancer. Strategies of gene therapy for breast cancer in ongoing clinical protocols can be divided into four: (1) suppression of oncogenes or transduction of tumor suppressors; (2) enhancement of immunological response to cancer cells; (3) transduction of suicide genes; and (4) protection of bone marrow using drug resistance genes. We have started a clinical study of gene therapy for breast cancer using multidrug resistance gene (MDR1), in which advanced or relapsed breast cancer patients received high dose chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT) with MDR1-transduced hemopoietic cells, and then were treated with docetaxel. Two patients have been treated so far, and in vivo enrichment of MDR1-transduced cells with docetaxel treatment after PBSCT was seen in both cases. Both patients are in complete remission and have no apparent adverse effect from MDR1 gene transduction.",
author = "Shunji Takahashi and Kiyohiko Hatake and Yoshikazu Sugimoto",
year = "2003",
month = "4",
language = "English",
volume = "30",
pages = "468--477",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "4",

}

TY - JOUR

T1 - Gene therapy for breast cancer

AU - Takahashi, Shunji

AU - Hatake, Kiyohiko

AU - Sugimoto, Yoshikazu

PY - 2003/4

Y1 - 2003/4

N2 - Breast cancer is sensitive to chemotherapy and endocrine therapy, but the prognosis of advanced or relapsed breast cancer is unsatisfactory. Gene therapy is promising as another useful therapeutic approach for advanced breast cancer. Strategies of gene therapy for breast cancer in ongoing clinical protocols can be divided into four: (1) suppression of oncogenes or transduction of tumor suppressors; (2) enhancement of immunological response to cancer cells; (3) transduction of suicide genes; and (4) protection of bone marrow using drug resistance genes. We have started a clinical study of gene therapy for breast cancer using multidrug resistance gene (MDR1), in which advanced or relapsed breast cancer patients received high dose chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT) with MDR1-transduced hemopoietic cells, and then were treated with docetaxel. Two patients have been treated so far, and in vivo enrichment of MDR1-transduced cells with docetaxel treatment after PBSCT was seen in both cases. Both patients are in complete remission and have no apparent adverse effect from MDR1 gene transduction.

AB - Breast cancer is sensitive to chemotherapy and endocrine therapy, but the prognosis of advanced or relapsed breast cancer is unsatisfactory. Gene therapy is promising as another useful therapeutic approach for advanced breast cancer. Strategies of gene therapy for breast cancer in ongoing clinical protocols can be divided into four: (1) suppression of oncogenes or transduction of tumor suppressors; (2) enhancement of immunological response to cancer cells; (3) transduction of suicide genes; and (4) protection of bone marrow using drug resistance genes. We have started a clinical study of gene therapy for breast cancer using multidrug resistance gene (MDR1), in which advanced or relapsed breast cancer patients received high dose chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT) with MDR1-transduced hemopoietic cells, and then were treated with docetaxel. Two patients have been treated so far, and in vivo enrichment of MDR1-transduced cells with docetaxel treatment after PBSCT was seen in both cases. Both patients are in complete remission and have no apparent adverse effect from MDR1 gene transduction.

UR - http://www.scopus.com/inward/record.url?scp=0038531102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038531102&partnerID=8YFLogxK

M3 - Article

C2 - 12722676

AN - SCOPUS:0038531102

VL - 30

SP - 468

EP - 477

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 4

ER -